CN111344398A - 分离的重组溶瘤腺病毒、药物组合物及其在***和/或癌症的药物中的用途 - Google Patents

分离的重组溶瘤腺病毒、药物组合物及其在***和/或癌症的药物中的用途 Download PDF

Info

Publication number
CN111344398A
CN111344398A CN201880061997.8A CN201880061997A CN111344398A CN 111344398 A CN111344398 A CN 111344398A CN 201880061997 A CN201880061997 A CN 201880061997A CN 111344398 A CN111344398 A CN 111344398A
Authority
CN
China
Prior art keywords
cells
cancer
oncolytic adenovirus
tumor
shpdl1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880061997.8A
Other languages
English (en)
Other versions
CN111344398B (zh
Inventor
绳纪坡
傅瑾
赵荣华
秦云
陈霖
康三毛
胡放
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Kangwanda Pharmaceutical Technology Co Ltd
Original Assignee
Hangzhou Converd Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Converd Co Ltd filed Critical Hangzhou Converd Co Ltd
Publication of CN111344398A publication Critical patent/CN111344398A/zh
Application granted granted Critical
Publication of CN111344398B publication Critical patent/CN111344398B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了分离的重组溶瘤腺病毒、药物组合物及其在***和/或癌症的药物中的用途。所述重组溶瘤腺病毒为选择复制型溶瘤腺病毒，并且该重组溶瘤腺病毒的基因组中整合有能够在肿瘤细胞中抑制PDL1表达的外源shRNA的编码序列。该病毒在正常原代细胞中的复制能力远远低于其在肿瘤细胞中的复制能力，并且所表达的shPDL1能够显著降低肿瘤细胞内高表达的PDL1蛋白水平，从而使溶瘤病毒的溶瘤杀伤作用和免疫细胞的抗肿瘤免疫刺激作用产生协同效果。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201880061997.8A 2017-09-28 2018-07-03 分离的重组溶瘤腺病毒、药物组合物及其在***和/或癌症的药物中的用途 Active CN111344398B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710899291.6A CN109576231B (zh) 2017-09-28 2017-09-28 分离的重组溶瘤腺病毒、药物组合物及其在***和/或癌症的药物中的用途
CN2017108992916 2017-09-28
PCT/CN2018/094264 WO2019062251A1 (zh) 2017-09-28 2018-07-03 分离的重组溶瘤腺病毒、药物组合物及其在***和/或癌症的药物中的用途

Publications (2)

Publication Number Publication Date
CN111344398A true CN111344398A (zh) 2020-06-26
CN111344398B CN111344398B (zh) 2022-03-22

Family

ID=65900481

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710899291.6A Active CN109576231B (zh) 2017-09-28 2017-09-28 分离的重组溶瘤腺病毒、药物组合物及其在***和/或癌症的药物中的用途
CN201880061997.8A Active CN111344398B (zh) 2017-09-28 2018-07-03 分离的重组溶瘤腺病毒、药物组合物及其在***和/或癌症的药物中的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710899291.6A Active CN109576231B (zh) 2017-09-28 2017-09-28 分离的重组溶瘤腺病毒、药物组合物及其在***和/或癌症的药物中的用途

Country Status (5)

Country Link
US (2) US11806374B2 (zh)
EP (1) EP3699270A4 (zh)
JP (1) JP7159304B2 (zh)
CN (2) CN109576231B (zh)
WO (2) WO2019062250A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110248671A (zh) * 2017-01-04 2019-09-17 杭州康万达医药科技有限公司 包含溶瘤痘病毒和nk细胞的治疗剂及其在***和/或癌症的药物中的应用
CN114632149A (zh) * 2020-12-16 2022-06-17 上海三维生物技术有限公司 溶瘤病毒和免疫调节剂在协同抑制晚期肝癌中的应用
WO2022179527A1 (zh) * 2021-02-23 2022-09-01 浙江大学医学院附属第一医院 治疗胰腺癌的组合物及其用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109576231B (zh) * 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在***和/或癌症的药物中的用途
CN111743923A (zh) * 2019-03-27 2020-10-09 北京康万达医药科技有限公司 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用
CN112011570B (zh) * 2019-05-31 2023-04-18 北京合生基因科技有限公司 特异杀伤肿瘤细胞的溶瘤病毒***及其应用
CN111089977A (zh) * 2019-12-30 2020-05-01 浙江科途医学科技有限公司 一种利用类器官检测溶瘤病毒有效性的方法
CN113774031B (zh) * 2020-06-10 2024-04-02 广州恩宝生物医药科技有限公司 一种复制型人腺病毒及其应用
CN113943715B (zh) * 2020-07-18 2024-04-26 上海元宋生物技术有限公司 一种重组溶瘤基因腺病毒及其构建方法与应用
CN114262691A (zh) * 2020-09-16 2022-04-01 杭州康万达医药科技有限公司 分离的能够用于表达外源基因的溶瘤腺病毒、载体、治疗剂及其用途
CN114164186B (zh) * 2021-11-15 2023-09-12 南京鼓楼医院 一种溶瘤腺病毒、其构建方法及其应用
CN114214457B (zh) * 2021-12-14 2023-10-17 福建省医学科学研究院 TCID50、MOI、GTU联合PFU综合评估腺病毒pAd-M3C滴度的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1384885A (zh) * 1999-10-07 2002-12-11 阿文蒂斯药物股份有限公司 重组腺病毒与腺病毒库的制备方法
CN1968717A (zh) * 2004-03-30 2007-05-23 延世大学工业教产学协力团 含有松驰素基因的基因送递***和使用松驰素的药物组合物
WO2017100127A1 (en) * 2015-12-06 2017-06-15 Boston Biomedical, Inc. ASYMMETRIC INTERFERING RNAs, AND COMPOSITIONS, USE, OR PREPARATION THEREOF
CN107208069A (zh) * 2014-07-16 2017-09-26 特兰斯吉恩股份有限公司 用于表达免疫检查点调节因子的溶瘤病毒
CN109576231A (zh) * 2017-09-28 2019-04-05 杭州康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在***和/或癌症的药物中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007855A2 (en) * 2003-07-14 2005-01-27 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF B7-H1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20060270016A1 (en) * 2003-11-14 2006-11-30 Holm Per S Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
SG158133A1 (en) 2004-12-31 2010-01-29 Sonne Holm Method for reversing multiple resistance in animal cells
KR100756055B1 (ko) * 2006-01-27 2007-09-07 연세대학교 산학협력단 신생혈관 생성을 조절하는 재조합 아데노바이러스
KR101248912B1 (ko) 2009-12-31 2013-03-29 한양대학교 산학협력단 항혈관신생 활성을 가지는 재조합 아데노바이러스
CN103221423B (zh) 2010-09-24 2015-09-30 昂克斯治疗有限公司 溶瘤腺病毒载体及与其相关的方法和用途
ES2708749T3 (es) * 2013-04-18 2019-04-11 Tilt Biotherapeutics Oy Terapia celular adoptiva mejorada
JP6857498B2 (ja) 2014-02-27 2021-04-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌を処置するための併用方法
GB201408297D0 (en) 2014-05-12 2014-06-25 Virttu Biolog Ltd Treatment of cancer
AU2015289081B2 (en) * 2014-07-16 2020-02-06 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
EP3270939A1 (en) * 2015-03-17 2018-01-24 TILT Biotherapeutics Oy Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
CN107849111B (zh) 2015-05-04 2022-02-22 Vcn生物科学有限公司 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途
US10533173B2 (en) 2015-05-05 2020-01-14 Jiangsu Micromedmark Biotech Co., Ltd. Precursor miRNA and applications in tumor therapy thereof
EP3411474A4 (en) * 2016-02-05 2019-09-11 Nant Holdings IP LLC COMPOSITIONS AND METHODS FOR EXPRESSION OF RECOMBINANT CXADR

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1384885A (zh) * 1999-10-07 2002-12-11 阿文蒂斯药物股份有限公司 重组腺病毒与腺病毒库的制备方法
CN1968717A (zh) * 2004-03-30 2007-05-23 延世大学工业教产学协力团 含有松驰素基因的基因送递***和使用松驰素的药物组合物
CN107208069A (zh) * 2014-07-16 2017-09-26 特兰斯吉恩股份有限公司 用于表达免疫检查点调节因子的溶瘤病毒
WO2017100127A1 (en) * 2015-12-06 2017-06-15 Boston Biomedical, Inc. ASYMMETRIC INTERFERING RNAs, AND COMPOSITIONS, USE, OR PREPARATION THEREOF
CN109576231A (zh) * 2017-09-28 2019-04-05 杭州康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在***和/或癌症的药物中的用途

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110248671A (zh) * 2017-01-04 2019-09-17 杭州康万达医药科技有限公司 包含溶瘤痘病毒和nk细胞的治疗剂及其在***和/或癌症的药物中的应用
CN110248671B (zh) * 2017-01-04 2023-07-04 杭州康万达医药科技有限公司 包含溶瘤痘病毒和nk细胞的治疗剂及其在***和/或癌症的药物中的应用
CN114632149A (zh) * 2020-12-16 2022-06-17 上海三维生物技术有限公司 溶瘤病毒和免疫调节剂在协同抑制晚期肝癌中的应用
WO2022179527A1 (zh) * 2021-02-23 2022-09-01 浙江大学医学院附属第一医院 治疗胰腺癌的组合物及其用途

Also Published As

Publication number Publication date
EP3699270A1 (en) 2020-08-26
CN111344398B (zh) 2022-03-22
EP3699270A4 (en) 2021-06-30
JP7159304B2 (ja) 2022-10-24
US11806374B2 (en) 2023-11-07
CN109576231A (zh) 2019-04-05
US20200276252A1 (en) 2020-09-03
WO2019062250A1 (zh) 2019-04-04
US20240100106A1 (en) 2024-03-28
WO2019062251A1 (zh) 2019-04-04
JP2021500872A (ja) 2021-01-14
CN109576231B (zh) 2022-03-25

Similar Documents

Publication Publication Date Title
CN111344398B (zh) 分离的重组溶瘤腺病毒、药物组合物及其在***和/或癌症的药物中的用途
CN110128550B (zh) 一种新型的同时阻断免疫检查点pd-l1和tigit的复制型溶瘤腺病毒和应用
WO2020192684A1 (zh) 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用
CN111315873B (zh) 分离的重组溶瘤痘病毒、药物组合物及其在***和/或癌症的药物中的用途
KR20170039774A (ko) 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템
CN112584849A (zh) 包含核酸及car修饰的免疫细胞的治疗剂及其应用
US20220339220A1 (en) Therapeutic agents comprising oncolytic vaccinia viruses and nk cells, and uses thereof for drugs for treatment of tumors and/or cancers
WO2015153417A1 (en) Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof
JP7420751B2 (ja) Ｉ型インターフェロン及びｃｄ４０－配位子を用いる腫瘍溶解性ウイルス又は抗原提示細胞媒介性癌治療
CN111606999B (zh) 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用
EP1553178B1 (en) Oncolytic virus growing selectively in tumor cells
CN110996980A (zh) 一种用于***的病毒
WO2021218802A1 (zh) 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
CN113891747A (zh) 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法
WO2021197507A1 (zh) 重组新城疫病毒及制备方法、重组质粒、及其应用
WO2021197506A1 (zh) 重组新城疫病毒及制备方法、重组质粒、及其应用
WO2023124973A1 (zh) 一种利用外源性抗原和治疗剂联合***的方法
US20240165175A1 (en) Muc16 promoter containing virus
US20230390320A1 (en) Cancer-specific trans-splicing ribozyme expressing immune checkpoint inhibitor, and use thereor
JP6069480B2 (ja) 複製可能偽型レトロウイルスベクターシステム
CN116590242A (zh) 一种重组溶瘤腺病毒及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200819

Address after: 901, 9 / F, Zhongdian information building, no.6, Zhongguancun South Street, Haidian District, Beijing 100086

Applicant after: Beijing kangwanda Pharmaceutical Technology Co., Ltd

Address before: 311121 7 storehouse, 4 Yuhang road 2959, Cang Qian street, Yuhang District, Hangzhou, Zhejiang.

Applicant before: HANGZHOU CONVERD Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant